Literature DB >> 25304005

Pharmacological treatment of chronic non-cancer pain in pediatric patients.

Eapen Mathew1, Eugene Kim, Kenneth R Goldschneider.   

Abstract

Chronic pain in children and young adults occurs frequently and contributes to early disability as well as personal and familial distress. A biopsychosocial approach to evaluation and treatment is recommended. Within this approach, there is a role for pharmacologic intervention. A variety of medications are used for chronic pain conditions in pediatric patients. Medication classes include anticonvulsants, muscle relaxants, antidepressants, opioids, local anesthetics, and anti-inflammatory drugs. Data is sparse, and most medications are used without condition-specific approval by national regulatory agencies such as the Food and Drug Administration in the US and the European Medicines Agency. In the absence of evidence on which to base practice, optimal drug therapy decisions rest on understanding proposed mechanisms of pain conditions, extrapolation from adult data-when such exists, and empirical and experiential knowledge. Drug delivery systems have evolved, and practitioners have to decide amongst not only medication classes, but also routes of delivery. Opioids are not recommended for use by non-pain specialists for the treatment of pediatric chronic pain, and even then the issues are more complex than can be addressed here. This article reviews the major medications used for pediatric chronic pain conditions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25304005     DOI: 10.1007/s40272-014-0092-2

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  137 in total

1.  A guide to diagnoses, indications, and contraindications for interventions in pediatric chronic pain.

Authors:  Alexandra Szabova; John Rose; Kenneth Goldschneider
Journal:  Int Anesthesiol Clin       Date:  2012

2.  Nonpharmacologic treatment of migraine with low-dose propranolol or amitriptyline.

Authors:  Tal Eidlitz-Markus; Yael Dlugatch; Yishai Haimi-Cohen; Hadassa Goldberg-Stern; Avraham Zeharia
Journal:  Pediatr Neurol       Date:  2012-06       Impact factor: 3.372

3.  Pharmacokinetics and safety of continuously applied lidocaine patches 5%.

Authors:  Arnold R Gammaitoni; Nancy A Alvarez; Bradley S Galer
Journal:  Am J Health Syst Pharm       Date:  2002-11-15       Impact factor: 2.637

4.  Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial.

Authors:  Lesley M Arnold; R Michael Gendreau; Robert H Palmer; Judy F Gendreau; Yong Wang
Journal:  Arthritis Rheum       Date:  2010-09

5.  Deficit of brain and skeletal muscle bioenergetics and low brain magnesium in juvenile migraine: an in vivo 31P magnetic resonance spectroscopy interictal study.

Authors:  R Lodi; P Montagna; S Soriani; S Iotti; C Arnaldi; P Cortelli; G Pierangeli; A Patuelli; P Zaniol; B Barbiroli
Journal:  Pediatr Res       Date:  1997-12       Impact factor: 3.756

6.  Baclofen for the treatment of acute low-back syndrome. A double-blind comparison with placebo.

Authors:  F Dapas; S F Hartman; L Martinez; B E Northrup; R T Nussdorf; H M Silberman; H Gross
Journal:  Spine (Phila Pa 1976)       Date:  1985-05       Impact factor: 3.468

Review 7.  Pediatric migraine: pharmacologic agents for prophylaxis.

Authors:  Lea S Eiland; Lauren S Jenkins; Spencer H Durham
Journal:  Ann Pharmacother       Date:  2007-06-05       Impact factor: 3.154

8.  Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial.

Authors:  G Cappello; M Spezzaferro; L Grossi; L Manzoli; L Marzio
Journal:  Dig Liver Dis       Date:  2007-04-08       Impact factor: 4.088

9.  Intravenous magnesium as acute treatment for headaches: a pediatric case series.

Authors:  Emily Gertsch; Sheila Loharuka; Kristine Wolter-Warmerdam; Suhong Tong; Allison Kempe; Sita Kedia
Journal:  J Emerg Med       Date:  2013-10-29       Impact factor: 1.484

Review 10.  Carbamazepine for chronic neuropathic pain and fibromyalgia in adults.

Authors:  Philip J Wiffen; Sheena Derry; R Andrew Moore; Eija A Kalso
Journal:  Cochrane Database Syst Rev       Date:  2014-04-10
View more
  4 in total

1.  A Secondary Analysis of Integrated Pediatric Chronic Pain Services Related to Cost Savings.

Authors:  Tiffany K Torigoe-Lai; Nicole E Mahrer; Margaret J Klein; Jeffrey I Gold
Journal:  J Clin Psychol Med Settings       Date:  2021-06

2.  Subanesthetic ketamine infusions for the treatment of children and adolescents with chronic pain: a longitudinal study.

Authors:  Kathy A Sheehy; Elena A Muller; Caroline Lippold; Mehdi Nouraie; Julia C Finkel; Zenaide M N Quezado
Journal:  BMC Pediatr       Date:  2015-12-01       Impact factor: 2.125

Review 3.  Pharmacological interventions for pain in children and adolescents with life-limiting conditions.

Authors:  Emma Beecham; Bridget Candy; Richard Howard; Renée McCulloch; Jo Laddie; Henrietta Rees; Victoria Vickerstaff; Myra Bluebond-Langner; Louise Jones
Journal:  Cochrane Database Syst Rev       Date:  2015-03-13

Review 4.  Comorbid chronic pain and opioid misuse in youth: Knowns, unknowns, and implications for behavioral treatment.

Authors:  Melissa Pielech; Claire E Lunde; Sara J Becker; Kevin E Vowles; Christine B Sieberg
Journal:  Am Psychol       Date:  2020-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.